STIM1 and its role in regulating cardiac metabolism
STIM1及其在心脏代谢中的调节作用
基本信息
- 批准号:10371868
- 负责人:
- 金额:$ 54.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse effectsAgeAmino AcidsAttenuatedCalciumCalcium SignalingCardiacCardiac MyocytesCardiac developmentCardiovascular DiseasesCell membraneCellsDiabetes MellitusDilated CardiomyopathyDiseaseElementsEnergy MetabolismEtiologyEukaryotic CellEventExhibitsFastingFatty AcidsFoundationsFunctional disorderGLUT 4 proteinGenetic TranscriptionGlucoseGlycolysisGoalsHeartHeart DiseasesHeart failureHomeostasisHormonesHypertrophyImpairmentIncidenceKetone BodiesKnockout MiceKnowledgeLipidsMetabolicMetabolismMitochondriaMolecularPathologyPathway interactionsPhosphorylationPhysiologicalPlayPost-Translational Protein ProcessingProductionPrognosisProteinsPyruvateQuality ControlRecurrenceRegulationReportingRepressionRoleSTIM1 geneSignal PathwaySignal TransductionSurvival RateSystemTestingUp-RegulationWorkloadcalcium metabolismcardiogenesisdiabetic cardiomyopathyeffective therapyfeedingflexibilityglucose metabolismheart functionheart metabolismimprovedinsightinsulin signalingmetabolic phenotypemortalitynovel therapeuticsoxidationpressurepyruvate dehydrogenaseresponserestoration
项目摘要
Mortality rates associated with cardiovascular disease have decreased significantly; however, the incidence of
heart failure continues to grow and 5-year survival rates remain at ~50%, underscoring the need to improve
our knowledge of the molecular underpinnings of this disease. The heart requires a high level of
metabolic flexibility to enable it to continuously adapt to changing workload demands throughout the day.
Substrate availability and hormone levels also fluctuate with fasting/feeding cycles, further demanding cardiac
metabolic flexibility. Loss of cardiac metabolic flexibility is a recurrent feature of cardiac disease, observed
during hypertrophy, heart failure and diabetic cardiomyopathy. Similarly, dysregulation of Ca2+ homeostasis is
a common element underlying the etiology of many cardiac diseases. Calcium is an established regulator of
cardiac metabolism and mitochondrial function, through direct allosteric interactions, posttranslational
modifications, and transcriptional events. However, despite established roles of Ca2+ in regulating cardiac
energy metabolism, the specific Ca2+ handling pathways involved are not well characterized and their
role in maintaining metabolic flexibility is not known. STromal Interaction Molecule-1 (STIM1) is a
ubiquitously expressed and highly evolutionarily conserved protein located in the ER/SR that is responsible for
regulating diverse Ca2+ signaling pathways in non-excitable cells and is recognized as a core element of all
mammalian Ca2+ signaling systems. Despite discovery of STIM1 in the heart approximately 20 years ago,
our knowledge about the physiological role of STIM1 in adult cardiomyocytes remains unclear and
controversial. We recently reported that cardiomyocyte deletion of STIM1 (crSTIM1-KO) precipitates contractile
dysfunction and dilated cardiomyopathy by 36 weeks of age. In young crSTIM1-KO mice prior to onset of
contractile dysfunction there was impaired glucose metabolism and insulin signaling combined with increased
lipid accumulation and an upregulation of lipogenic proteins. This metabolic phenotype is very similar to the
cardiac metabolic signature observed during diabetes, a well characterized example of metabolic inflexibility.
Collectively, these observations have led to the hypothesis that STIM1 is a previously unrecognized
regulator of cardiac metabolism and mitochondrial function and that decreased STIM1 contributes to
the adverse effects of diabetes on the heart. To test this hypothesis, we will 1) Define fully the extent to
which STIM1 regulates cardiac metabolism; 2) Establish the mechanisms by which STIM1 influences
mitochondrial function in the heart and 3) Determine how diabetes regulates STIM1 levels and whether loss of
STIM1 contributes to the adverse effects of diabetes on the heart. The successful completion of this proposal
will provide significant new insights into the role of STIM1 in regulating cardiac metabolism and mitochondrial
function and provide the foundation for improved understanding regarding the contribution of STIM1
dysregulation to cardiac metabolic inflexibility and contractile dysfunction during disease states.
与心血管疾病相关的死亡率显着下降;然而,发生率
心力衰竭持续增加,5 年生存率保持在 50% 左右,这凸显了改善的必要性
我们对这种疾病的分子基础的了解。心脏需要高水平的
代谢灵活性使其能够不断适应全天不断变化的工作量需求。
底物可用性和激素水平也会随着禁食/喂养周期而波动,进一步要求心脏
代谢灵活性。据观察,心脏代谢灵活性的丧失是心脏病的一个反复出现的特征
在肥厚、心力衰竭和糖尿病心肌病期间。同样,Ca2+ 稳态失调是
许多心脏病病因学的共同因素。钙是一种既定的调节剂
心脏代谢和线粒体功能,通过直接变构相互作用,翻译后
修饰和转录事件。然而,尽管 Ca2+ 在调节心脏方面的作用已被证实
能量代谢中,所涉及的特定 Ca2+ 处理途径尚未得到很好的表征,并且它们的
在维持代谢灵活性方面的作用尚不清楚。 STromal 相互作用分子-1 (STIM1) 是一种
普遍表达且高度进化保守的蛋白质,位于 ER/SR 中,负责
调节非兴奋性细胞中多种 Ca2+ 信号通路,被认为是所有细胞的核心要素
哺乳动物 Ca2+ 信号系统。尽管大约 20 年前在心脏中发现了 STIM1,
我们对 STIM1 在成人心肌细胞中的生理作用的了解仍不清楚
有争议的。我们最近报道了心肌细胞 STIM1 缺失 (crSTIM1-KO) 会导致收缩
36周龄时出现功能障碍和扩张型心肌病。在发病前的年轻 crSTIM1-KO 小鼠中
收缩功能障碍,葡萄糖代谢和胰岛素信号传导受损,同时增加
脂质积累和脂肪生成蛋白的上调。这种代谢表型与
在糖尿病期间观察到的心脏代谢特征,这是代谢不灵活的一个典型例子。
总的来说,这些观察结果得出了这样的假设:STIM1 是一种以前未被识别的基因。
STIM1 的减少有助于心脏代谢和线粒体功能的调节
糖尿病对心脏的不利影响。为了检验这个假设,我们将 1) 完全定义
其中 STIM1 调节心脏代谢; 2)建立STIM1影响的机制
心脏中的线粒体功能,以及 3) 确定糖尿病如何调节 STIM1 水平以及是否丧失
STIM1 会加剧糖尿病对心脏的不利影响。本次提案的顺利完成
将为 STIM1 在调节心脏代谢和线粒体中的作用提供重要的新见解
功能并为加深对 STIM1 贡献的理解奠定基础
疾病状态下心脏代谢僵化和收缩功能障碍的失调。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN C CHATHAM其他文献
JOHN C CHATHAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN C CHATHAM', 18)}}的其他基金
The role of protein O-linked N-Acetylglucosamine in regulating cardiac physiology
蛋白O-连接的N-乙酰氨基葡萄糖在调节心脏生理学中的作用
- 批准号:
10213829 - 财政年份:2020
- 资助金额:
$ 54.66万 - 项目类别:
STIM1 and its role in regulating cardiac metabolism
STIM1及其在心脏代谢中的调节作用
- 批准号:
10592268 - 财政年份:2020
- 资助金额:
$ 54.66万 - 项目类别:
Administrative Supplement to Award "Circadian regulation of vascular aging"
“血管老化的昼夜节律调节”奖行政补充
- 批准号:
10283788 - 财政年份:2019
- 资助金额:
$ 54.66万 - 项目类别:
Rapid modulation of hippocampal GABAergic Inhibition by O-GlcNAcylation
O-GlcNAc 酰化快速调节海马 GABA 能抑制
- 批准号:
9765783 - 财政年份:2019
- 资助金额:
$ 54.66万 - 项目类别:
Aberrant Circadian Regulation of Autophagy in the Heart During Diabetes
糖尿病期间心脏自噬的异常昼夜节律调节
- 批准号:
10288158 - 财政年份:2018
- 资助金额:
$ 54.66万 - 项目类别:
Aberrant Circadian Regulation of Autophagy in the Heart During Diabetes
糖尿病期间心脏自噬的异常昼夜节律调节
- 批准号:
9543678 - 财政年份:2018
- 资助金额:
$ 54.66万 - 项目类别:
Aberrant Circadian Regulation of Autophagy in the Heart During Diabetes
糖尿病期间心脏自噬的异常昼夜节律调节
- 批准号:
10078980 - 财政年份:2018
- 资助金额:
$ 54.66万 - 项目类别:
Disruption of the Clock O-GlcNAc axis in diabetic cardiomyopathy
糖尿病心肌病中时钟 O-GlcNAc 轴的破坏
- 批准号:
8814019 - 财政年份:2014
- 资助金额:
$ 54.66万 - 项目类别:
相似国自然基金
儿童药品不良反应主动监测中时序处理策略的方法学研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention
使用新型 MHealth 干预措施针对年轻人中酒精与阿片类药物的同时使用
- 批准号:
10456380 - 财政年份:2023
- 资助金额:
$ 54.66万 - 项目类别:
Traumatic Brain Injury Anti-Seizure Prophylaxis in the Medicare Program
医疗保险计划中的创伤性脑损伤抗癫痫预防
- 批准号:
10715238 - 财政年份:2023
- 资助金额:
$ 54.66万 - 项目类别:
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
减少年轻成年睾丸癌幸存者不良后果的生物行为干预
- 批准号:
10736501 - 财政年份:2023
- 资助金额:
$ 54.66万 - 项目类别:
KLOTHO and Resilience to Synaptic Dysfunction in Preclinical AD
KLOTHO 和临床前 AD 中突触功能障碍的恢复力
- 批准号:
10587987 - 财政年份:2023
- 资助金额:
$ 54.66万 - 项目类别:
The Role of Outpatient Diuretic Therapy in Bronchopulmonary Dysplasia
门诊利尿疗法在支气管肺发育不良中的作用
- 批准号:
10663469 - 财政年份:2023
- 资助金额:
$ 54.66万 - 项目类别: